• Dr. Charles Chiu

    Dr. Charles Chiu
    Assistant Professor, Laboratory Medicine & Medicine/Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics & Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory

    Dr. Chiu holds joint appointments as an Associate Professor of Laboratory Medicine and Medicine/Infectious Diseases at UCSF, Director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC), Assistant Director of the UCSF Clinical Microbiology Laboratory, and a staff infectious diseases physician at UCSF.

    After completing undergraduate work at UC Berkeley, he received his Ph.D. in biophysics and his M.D. at UCLA, and subsequently completed residency training in internal medicine and fellowship in infectious diseases at UCSF. Dr. Chiu is an expert in the development and implementation of advanced genomic technologies – microarrays and next-generation sequencing (NGS) – for pathogen discovery and clinical assay validation in the microbiology laboratory, with over 50 patents and peer-reviewed publications on these topics.

  • Dr. Tony Gordon

    Dr. Tony Gordon
    Managing Director (USA) & Laboratory Director (UK), Genesis Genetics

    Dr. Gordon is currently the the Managing Director for Genesis Genetics USA laboratories and the Laboratory Director for Genesis Genetics UK laboratories. Dr. Gordon is also a UK State Registered Clinical scientist, with nearly 20 years’ experience in clinical diagnostics and is a Fellow of the Society of Biology.

    After obtaining a Ph.D. in Carcinogenesis research at the University of Nottingham in 1995, Dr. Gordon carried out research for 7 years at the Institute of Cancer Research (London, UK) in Molecular Cytogenetics. Between 2002 and 2005, Dr. Gordon ran the microarray divisions of both MWG Biotech and Tecan. In early 2006, Dr. Gordon joined BlueGnome to start their CytoChip microarray product line and then, in 2008, was fundamental in developing the 24sure product line to bring BlueGnome’s copy number microarray expertise to pre-implantation genetic screening (PGS). In September 2012 BlueGnome was sold to Illumina for $88M.

     

  • Dr. Sean Levy

    Dr. Sean Levy
    Faculty Investigator, HudsonAlpha Institute for Biotechnology

    Dr. Levy currently directs the Genomic Services Laboratory at HudsonAlpha supporting projects that utilize genomic technologies from laboratories around the world. He received his graduate and postdoctoral training from Emory University. Dr. Levy served  on the faculty at Vanderbilt University Medical Center and was the founding director of the Vanderbilt Microarray Shared Resource until 2009.

     His current research areas include (1) technology development and optimization, (2) de novo mutation detection and the role of these mutations in neurological disease including Autism and Schizophrenia, and (3) the molecular responses of the immune system and microbiome to vaccines, organ transplant procedures and chemotherapy.

  • Dr. James Hadfield

    Dr. James Hadfield
    Director, Genomics Core facility laboratory at the Cambridge Institute

    Dr. Hadfield currently directs the Genomics Core facility laboratory at the Cancer Research UK Cambridge Institute, a department of the University of Cambridge. It offers genomic services, primarily Illumina next-generation sequencing, for scientists at CRUK-CI, Gurdon, MRC-LMB, and other departments at the University of Cambridge. He received his Ph.D. in Genomics in 2014 at the University of East Anglia.

    As an expert in genomic and next-generation sequencing technologies, Dr. Hadfield is closely involved in the NGS community by maintaining and writing for the Core Genomics blog. He is currently seconded with Genomics England as a sequencing expert for the 100,000 genomes project.